Advertisement
Advertisement
U.S. markets open in 2 hours 47 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Relmada Therapeutics, Inc. (RLMD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
18.83-0.72 (-3.68%)
At close: 1:00PM EST
18.83 0.00 (0.00%)
After hours: 01:01PM EST
Advertisement

Relmada Therapeutics, Inc.

880 Third Avenue
12th Floor
New York, NY 10022
United States
646 876 3459
http://www.relmada.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBACEO & Director900kN/A1960
Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBAChief Financial Officer685.44kN/A1964
Mr. Charles S. Ence CPA, M.B.A.Chief Accounting & Compliance Officer453.75kN/A1965
Dr. Paolo Manfredi M.D., Ph.D.Chief Scientific OfficerN/AN/A1962
Ms. Gina DiGuglielmoVP & Head of Clinical OperationsN/AN/AN/A
Dr. Marc de Somer M.B.A., M.D., M.P.H., M.Sc.Sr. VP of Clinical Devel.N/AN/AN/A
Dr. Marco Pappagallo M.D.Chief Medical OfficerN/AN/A1958
Dr. Richard M. ManganoConsultantN/AN/A1950
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Corporate Governance

Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement